Ultragenyx reports inducement grant under nasdaq listing rule 5635(c)(4)

Novato, calif., march 19, 2025 (globe newswire) -- ultragenyx pharmaceutical inc. (nasdaq: rare), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 21,806 restricted stock units of the company's common stock to 16 newly hired non-executive officers of the company. the awards were approved by the compensation committee of the company's board of directors and granted under the ultragenyx employment inducement plan, with a grant date of march 16, 2025, as an inducement material to the new employees entering into employment with ultragenyx in accordance with nasdaq listing rule 5635(c)(4).
NDAQ Ratings Summary
NDAQ Quant Ranking